ArticleHemaSphere2023

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Manuel Gotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.